MCM
FOLD

Moore Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Moore Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,000
Closed -$1.95M – 712
2025
Q4 		$1.95M Buy
+137,000
New +$1.35M 0.03% 389
2017
Q4 		– Sell
-100,000
Closed -$1.51M – 268
2017
Q3 		$1.51M Buy
+100,000
New +$1.32M 0.03% 174
2016
Q1 		– Sell
-125,000
Closed -$1.21M – 270
2015
Q4 		$1.21M Hold
125,000
– – 0.04% 246
2015
Q3 		$1.75M Sell
125,000
-150,000
-55% -$2.35M 0.08% 213
2015
Q2 		$3.89M Buy
275,000
+134,359
+96% +$1.62M 0.08% 231
2015
Q1 		$1.53M Sell
140,641
-84,359
-37% -$744K 0.03% 308
2014
Q4 		$1.87M Buy
+225,000
New +$1.54M 0.06% 232

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Moore Capital Management's FOLD Position: Q1 2026 in Review

Moore Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 137,000 shares — an estimated $1.95M sold.

Moore Capital Management first reported a position in FOLD in Q4 2014 and held it in 7 quarters. The position peaked at $3.89M in Q2 2015. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Moore Capital Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 137,000 Amicus Therapeutics shares in Q1 2026, an estimated $1.95M.
  • Moore Capital Management first reported a position in Amicus Therapeutics in Q4 2014 and held it in 7 quarters.
  • Moore Capital Management's Amicus Therapeutics position peaked at $3.89M in Q2 2015.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.